# US 2026/0062755 A1 · Prediction and monitoring of immunotherapy in cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0062755 A1
- Document ID: US20260062755A1
- Status: Published application
- Kind: A1
- Application number: 19/102,702
- Filed: 2023-07-21
- Published: 2026-03-05
- Earliest claimed: 2022-08-12
- Assignees: InnoSIGN B.V.
- Applicants: InnoSIGN B.V.
- Inventors: Martijn Theodorus Lambert Akse; Paul Arnold Van De Wiel; Laurentius Henricus Franciscus Maria Holtzer; Anne Godefrida Catharina Van Brussel
- Web page: https://patentgrep.com/patent/US20260062755A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- A61K 45/00: Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/112: Disease subtyping, staging or classification
- C12Q 2600/158: Expression markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention relates to a method for predicting whether a subject with cancer can successfully be treated with an immunotherapy. The method is based on measuring the TGFbeta and/or the MAPK pathway activity in a sample obtained from the subject, wherein a low TGFbeta and/or MAPK pathway activity indicates that immunotherapy is likely successful and a high TGFbeta and/or MAPK pathway activity indicates that immunotherapy is not likely to be successful. The invention further relates to an immunotherapy for use in the treatment of cancer, the use comprising determining the TGFbeta and/or MAPK pathway activity and administering the immunotherapy if the treatment is deemed likely to succeed. The invention further relates to kits of parts and their uses in the methods described herein.

## Claims

### Claim 1

A method of predicting or monitoring a treatment response of a subject with cancer to immunotherapy, wherein the method is based on a sample obtained from the subject, the method comprising:
determining TGFbeta cellular signaling pathway activity in the sample obtained from the subject, wherein an increased TGFbeta cellular signaling pathway activity correlates with a decreased probability of a favorable treatment response to immunotherapy by the subject and wherein a decreased TGFbeta cellular signaling pathway activity correlates with an increased probability of a favorable treatment response to immunotherapy by the subject; and
making a prediction about the subject's treatment response to immunotherapy based on the determined TGFbeta cellular signaling pathway activity in the sample obtained from the subject,
wherein the TGFbeta cellular signaling pathway activity is determined based on the expression levels of three or more TGFbeta cellular signaling pathway target genes selected from: ANGPTL4, CDC42EP3, CDKN1A, CDKN2B, CCN2, GADD45A, GADD45B, HMGA2, ID1, IL11, INPP5D, JUNB, MMP2, MMP9, NKX2-5, OVOL1, PDGFB, PTHLH, SERPINE1, SGK1, SKIL, SMAD4, SMAD5, SMAD6, SMAD7, SNAI1, SNAI2, TIMP1, and VEGFA; and
wherein the immunotherapy is an immune checkpoint inhibitor.

### Claim 2 (depends on 1)

The m method of claim 1, wherein the method further comprises comparing the determined TGFbeta cellular signaling pathway activity with a predetermined threshold, and wherein the prediction is based on a comparison of the determined TGFbeta cellular signaling pathway activity with the predetermined threshold.

### Claim 3 (depends on 1)

The m method of claim 1, wherein the method comprises:
receiving expression levels of three or more target genes of the TGFbeta cellular signaling pathway measured in the sample of the subject, wherein the method is a computer implemented method, or wherein the method comprises determining expression levels of three or more target genes of the TGFbeta cellular signaling pathway in a sample obtained from the subject.

### Claim 4 (depends on 1)

The method of claim 1, wherein the determining the TGFbeta cellular signaling pathway activity comprises determining an activity level of a TGFbeta transcription factor (TF) element in the sample of the subject, the TGFbeta TF element controlling transcription of the three or more TGFbeta cellular signaling pathway target genes, the determining being based on evaluating a calibrated mathematical pathway model relating the expression levels of the three or more TGFbeta target genes to the activity level of the TGFbeta TF element.

### Claim 5 (depends on 1)

The m method of claim 1, wherein the immune checkpoint inhibitor is an inhibitor of PD-1 or PD-L1, and wherein the immune checkpoint inhibitor is selected from a group consisting of Pembrolizumab (formerly MK-3475 or lambrolizumab, Keytruda), Nivolumab (Opdivo), Cemiplimab (Libtayo), Dostarlimab (Jemperli), Retifanlimab (Zynyz), Vopratelimab (JTX-4014), Spartalizumab (PDR001), Camrelizumab (SHR1210) Sintilimab (IBI308), Tislelizumab (BGB-A317), Toripalimab (JS 001), INCMGA00012 (MGA012), AMP-224, AMP-514 (MEDI0680), Acrixolimab (YBL-006), Atezolizumab (Tecentriq), Avelumab (Bavencio), Durvalumab (Imfinzi), KN035, Cosibelimab (CK-301), AUNP12, CA-170, and BMS-986189.

### Claim 6 (depends on 1)

The method of claim 1, wherein the sample is a tissue sample, a blood sample, a biopsy, or a sample from the subject comprising cells.

### Claim 7 (depends on 2)

The method of claim 2, wherein the threshold is predetermined in a set of samples obtained from a cohort of cancer patients.

### Claim 8 (depends on 1)

The method of claim 1, wherein the treatment response of the subject is favorable or non-favorable response to the immunotherapy treatment.

### Claim 9 (depends on 1)

The method of claim 1, wherein the response is complete response, partial response, stable disease, or disease progression.

### Claim 10 (depends on 1)

The method of claim 1, wherein the method further comprises providing a treatment advice to a medical care giver, wherein the treatment advice is to provide the immunotherapy.

### Claim 11 (depends on 1)

The method of claim 1, wherein the method is for monitoring a treatment response, wherein the method further comprises providing a continuation advice to a medical care giver, wherein the continuation advice is to continue a current immunotherapy treatment strategy or to change the current immunotherapy treatment strategy.

### Claim 12 (depends on 1)

The method of claim 1, wherein the TGFbeta cellular signaling pathway activity is determined based on expression levels of three or more TGFbeta cellular signaling pathway target genes selected from: ANGPTL4, CDKN1A, CTGF, GADD45A, GADD45B, ID1, IL11, JUNB, MMP2, MMP9, PDGFB, SERPINE1, SGK1, SKIL, SMAD4, SMAD7, SNAI1, TIMP1, and VEGFA, or wherein the TGFbeta cellular signaling pathway activity is determined based on expression levels of three or more TGFbeta cellular signaling pathway target genes selected from: ANGPTL4, CTGF, IL11, JUNB, MMP2, SERPINE1, SGK1, SKIL, SMAD7, and VEGFA.

### Claim 13

A method for using immunotherapy in the treatment of cancer in a subject diagnosed with cancer, comprising:
determining TGFbeta cellular signaling pathway activity in sample obtained from the subject diagnosed with cancer, wherein an increased TGFbeta cellular signaling pathway activity correlates with a decreased probability of a favorable response to immunotherapy by the subject and wherein a decreased TGFbeta cellular signaling pathway activity correlates with an increased probability of a favorable response to immunotherapy by the subject; and
making a prediction about the treatment response based on the determined TGFbeta cellular signaling pathway activity;
wherein the TGFbeta cellular signaling pathway activity is determined based on the expression levels of three or more TGFbeta cellular signaling pathway target genes selected from: ANGPTL4, CDC42EP3, CDKN1A, CDKN2B, CCN2, GADD45A, GADD45B, HMGA2, ID1, IL11, INPP5D, JUNB, MMP2, MMP9, NKX2-5, OVOL1, PDGFB, PTHLH, SERPINE1, SGK1, SKIL, SMAD4, SMAD5, SMAD6, SMAD7, SNAI1, SNAI2, TIMP1, and VEGFA; and
wherein the immunotherapy is an immune checkpoint inhibitor.

### Claim 14 (depends on 13)

The method of claim 13, wherein the immune checkpoint inhibitor is an inhibitor of PD-1 or PD-L1, and wherein the immune checkpoint inhibitor is selected from a group consisting of Pembrolizumab (formerly MK-3475 or lambrolizumab, Keytruda), Nivolumab (Opdivo), Cemiplimab (Libtayo), Dostarlimab (Jemperli), Retifanlimab (Zynyz), Vopratelimab (JTX-4014), Spartalizumab (PDR001), Camrelizumab (SHR1210) Sintilimab (IBI308), Tislelizumab (BGB-A317), Toripalimab (JS 001), INCMGA00012 (MGA012), AMP-224, AMP-514 (MEDI0680), Acrixolimab (YBL-006), Atezolizumab (Tecentriq), Avelumab (Bavencio), Durvalumab (Imfinzi), KN035, Cosibelimab (CK-301), AUNP12, CA-170, and BMS-986189.

### Claim 15

A kit of parts in predicting or monitoring an immunotherapy treatment response of a subject with cancer, the kit comprising:
components for determining expression levels of three or more genes selected from: ANGPTL4, CDC42EP3, CDKN1A, CDKN2B, CCN2, GADD45A, GADD45B, HMGA2, ID1, IL11, INPP5D, JUNB, MMP2, MMP9, NKX2-5, OVOL1, PDGFB, PTHLH, SERPINE1, SGK1, SKIL, SMAD4, SMAD5, SMAD6, SMAD7, SNAI1, SNAI2, TIMP1, and VEGFA.
